1
|
How-Kit A, Sahbatou M, Hardy LM, Tessier NP, Schiavon V, Le Buanec H, Sebaoun JM, Blanché H, Zagury JF, Deleuze JF. Correction to: The CEPH aging cohort and biobank: a valuable collection of biological samples from exceptionally long‑lived French individuals and their offspring for longevity studies. GeroScience 2024; 46:3503-3505. [PMID: 38273141 PMCID: PMC11009164 DOI: 10.1007/s11357-024-01085-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2024] Open
Affiliation(s)
- Alexandre How-Kit
- Laboratory for Genomics, Foundation Jean Dausset - CEPH, Paris, France.
- Laboratory of Excellence GenMed, Paris, France.
| | - Mourad Sahbatou
- Laboratory for Genomics, Foundation Jean Dausset - CEPH, Paris, France
| | - Lise M Hardy
- Laboratory for Genomics, Foundation Jean Dausset - CEPH, Paris, France
- Laboratory of Excellence GenMed, Paris, France
| | - Nicolas P Tessier
- Laboratory for Genomics, Foundation Jean Dausset - CEPH, Paris, France
- Laboratory of Excellence GenMed, Paris, France
| | - Valérie Schiavon
- INSERM U976 ‑ HIPI Unit, Saint-Louis Research Institute, University of Paris, Paris, France
| | - Hélène Le Buanec
- INSERM U976 ‑ HIPI Unit, Saint-Louis Research Institute, University of Paris, Paris, France
| | - Jean-Marc Sebaoun
- Centre de Ressources Biologiques, Foundation Jean Dausset - CEPH, Paris, France
| | - Hélène Blanché
- Laboratory of Excellence GenMed, Paris, France
- Centre de Ressources Biologiques, Foundation Jean Dausset - CEPH, Paris, France
| | - Jean-François Zagury
- Équipe Génomique, Bioinformatique et Chimie Moléculaire (EA 7528), Conservatoire National Des Arts et Métiers, HESAM Université, Paris, France
| | - Jean-François Deleuze
- Laboratory for Genomics, Foundation Jean Dausset - CEPH, Paris, France.
- Laboratory of Excellence GenMed, Paris, France.
- Centre de Ressources Biologiques, Foundation Jean Dausset - CEPH, Paris, France.
- Centre National de Recherche en Génomique Humaine, CEA, Institut François Jacob, Evry, France.
| |
Collapse
|
2
|
How-Kit A, Sahbatou M, Hardy LM, Tessier NP, Schiavon V, Le Buanec H, Sebaoun JM, Blanché H, Zagury JF, Deleuze JF. The CEPH aging cohort and biobank: a valuable collection of biological samples from exceptionally long-lived French individuals and their offspring for longevity studies. GeroScience 2024; 46:2681-2695. [PMID: 38141157 PMCID: PMC10828222 DOI: 10.1007/s11357-023-01037-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Accepted: 12/06/2023] [Indexed: 12/24/2023] Open
Abstract
The increasing aging of the human population is currently and for the coming decades a major public health issue in many countries, requiring the implementation of global public health policies promoting healthy and successful aging. Individuals are not equal in the face of aging and some can present exceptional healthspan and/or lifespan, which are notably influenced by both genetic and environmental factors. Research and studies on human aging, healthy aging and longevity should rely in particular on cohorts of long-lived individuals, also including biological samples allowing studies on the biology of aging and longevity. In this manuscript, we provide for the first time a complete description of the CEPH (Centre d'Etude du Polymophisme Humain) Aging cohort, an exceptional cohort recruited during the 90s to 2000s, including more than 1700 French long-lived individuals (≥ 90 years old) born between 1875 and 1916 as well as for some of them their siblings and offspring. Among the participants, 1265 were centenarians, including 255 semi-supercentenarians ([105-110] years old) and 25 supercentenarians (≥ 110 years old). The available anthropometric, epidemiologic and clinical data for the cohort participants are described and especially the collection of blood-derived biological samples associated with the cohort which includes DNA, cryopreserved cells and cell lines, plasma, and serum. This biological collection from the first cohort of centenarians in the world is an inestimable resource for ongoing and future molecular, cellular, and functional studies aimed at deciphering the mechanisms of human (successful) aging and longevity.
Collapse
Affiliation(s)
- Alexandre How-Kit
- Laboratory for Genomics, Foundation Jean Dausset - CEPH, Paris, France.
- Laboratory of Excellence GenMed, Paris, France.
| | - Mourad Sahbatou
- Laboratory for Genomics, Foundation Jean Dausset - CEPH, Paris, France
| | - Lise M Hardy
- Laboratory for Genomics, Foundation Jean Dausset - CEPH, Paris, France
- Laboratory of Excellence GenMed, Paris, France
| | - Nicolas P Tessier
- Laboratory for Genomics, Foundation Jean Dausset - CEPH, Paris, France
- Laboratory of Excellence GenMed, Paris, France
| | - Valérie Schiavon
- INSERM U976 - HIPI Unit, Saint-Louis Research Institute, University of Paris, Paris, France
| | - Hélène Le Buanec
- INSERM U976 - HIPI Unit, Saint-Louis Research Institute, University of Paris, Paris, France
| | - Jean-Marc Sebaoun
- Centre de Ressources Biologiques, Foundation Jean Dausset - CEPH, Paris, France
| | - Hélène Blanché
- Laboratory of Excellence GenMed, Paris, France
- Centre de Ressources Biologiques, Foundation Jean Dausset - CEPH, Paris, France
| | - Jean-François Zagury
- Équipe Génomique, Bioinformatique et Chimie Moléculaire (EA 7528), Conservatoire National Des Arts et Métiers, HESAM Université, Paris, France
| | - Jean-François Deleuze
- Laboratory for Genomics, Foundation Jean Dausset - CEPH, Paris, France.
- Laboratory of Excellence GenMed, Paris, France.
- Centre de Ressources Biologiques, Foundation Jean Dausset - CEPH, Paris, France.
- Centre National de Recherche en Génomique Humaine, CEA, Institut François Jacob, Evry, France.
| |
Collapse
|
3
|
Buanec HL, Schiavon V, Merandet M, How-Kit A, Bergerat D, Fombellida-Lopez C, Bensussan A, Bouaziz JD, Burny A, Darcis G, Song H, Sajadi MM, Kottilil S, Gallo RC, Zagury D. Early elevated IFNα is a key mediator of HIV pathogenesis. Commun Med (Lond) 2024; 4:53. [PMID: 38504106 PMCID: PMC10951235 DOI: 10.1038/s43856-024-00454-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2023] [Accepted: 02/07/2024] [Indexed: 03/21/2024] Open
Abstract
BACKGROUND A complete understanding of the different steps of HIV replication and an effective drug combination have led to modern antiretroviral regimens that block HIV replication for decades, but these therapies are not curative and must be taken for life. "Elite controllers" (ECs) is a term for the 0.5% of HIV-infected persons requiring no antiretroviral therapy, whose status may point the way toward a functional HIV cure. Defining the mechanisms of this control may be key to understanding how to replicate this functional cure in others. METHODS In ECs and untreated non-EC patients, we compared IFNα serum concentration, distribution of immune cell subsets, and frequency of cell markers associated with immune dysfunction. We also investigated the effect of an elevated dose of IFNα on distinct subsets within dendritic cells, natural killer cells, and CD4+ and CD8 + T cells. RESULTS Serum IFNα was undetectable in ECs, but all immune cell subsets from untreated non-EC patients were structurally and functionally impaired. We also show that the altered phenotype and function of these cell subsets in non-EC patients can be recapitulated when cells are stimulated in vitro with high-dose IFNα. CONCLUSIONS Elevated IFNα is a key mediator of HIV pathogenesis.
Collapse
Affiliation(s)
- Hélène Le Buanec
- Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010, Paris, France
| | - Valérie Schiavon
- Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010, Paris, France
| | - Marine Merandet
- Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010, Paris, France
| | | | - David Bergerat
- Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010, Paris, France
| | - Céline Fombellida-Lopez
- Laboratory of Infectious Diseases, GIGA-I3, GIGA-Institute University of Liege, 4000, Liege, Belgium
| | - Armand Bensussan
- Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010, Paris, France
| | - Jean-David Bouaziz
- Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010, Paris, France
- Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Arsène Burny
- Laboratory of Molecular Biology, Gembloux Agrobiotech, University of Liège, Liège, Belgium
- Global Virus Network, Baltimore, MD, 21201, USA
| | - Gilles Darcis
- Laboratory of Infectious Diseases, GIGA-I3, GIGA-Institute University of Liege, 4000, Liege, Belgium
| | - Hongshuo Song
- Institute of Human Virology, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA
| | - Mohammad M Sajadi
- Global Virus Network, Baltimore, MD, 21201, USA
- Institute of Human Virology, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA
- University of Maryland School of Medicine, Baltimore, MD, 21201, USA
| | - Shyamasundaran Kottilil
- Global Virus Network, Baltimore, MD, 21201, USA
- Institute of Human Virology, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA
- University of Maryland School of Medicine, Baltimore, MD, 21201, USA
| | - Robert C Gallo
- Global Virus Network, Baltimore, MD, 21201, USA.
- Institute of Human Virology, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA.
| | | |
Collapse
|
4
|
Le Buanec H, Schiavon V, Merandet M, How-Kit A, Song H, Bergerat D, Fombellida-Lopez C, Bensussan A, Bouaziz JD, Burny A, Darcis G, Sajadi MM, Kottilil S, Zagury D, Gallo RC. IFNα induces CCR5 in CD4 + T cells of HIV patients causing pathogenic elevation. Commun Med (Lond) 2024; 4:52. [PMID: 38504093 PMCID: PMC10951336 DOI: 10.1038/s43856-024-00453-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2023] [Accepted: 02/07/2024] [Indexed: 03/21/2024] Open
Abstract
BACKGROUND Among people living with HIV, elite controllers (ECs) maintain an undetectable viral load, even without receiving anti-HIV therapy. In non-EC patients, this therapy leads to marked improvement, including in immune parameters, but unlike ECs, non-EC patients still require ongoing treatment and experience co-morbidities. In-depth, comprehensive immune analyses comparing EC and treated non-EC patients may reveal subtle, consistent differences. This comparison could clarify whether elevated circulating interferon-alpha (IFNα) promotes widespread immune cell alterations and persists post-therapy, furthering understanding of why non-EC patients continue to need treatment. METHODS Levels of IFNα in HIV-infected EC and treated non-EC patients were compared, along with blood immune cell subset distribution and phenotype, and functional capacities in some cases. In addition, we assessed mechanisms potentially associated with IFNα overload. RESULTS Treatment of non-EC patients results in restoration of IFNα control, followed by marked improvement in distribution numbers, phenotypic profiles of blood immune cells, and functional capacity. These changes still do not lead to EC status, however, and IFNα can induce these changes in normal immune cell counterparts in vitro. Hypothesizing that persistent alterations could arise from inalterable effects of IFNα at infection onset, we verified an IFNα-related mechanism. The protein induces the HIV coreceptor CCR5, boosting HIV infection and reducing the effects of anti-HIV therapies. EC patients may avoid elevated IFNα following on infection with a lower inoculum of HIV or because of some unidentified genetic factor. CONCLUSIONS Early control of IFNα is essential for better prognosis of HIV-infected patients.
Collapse
Affiliation(s)
- Hélène Le Buanec
- Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010, Paris, France
| | - Valérie Schiavon
- Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010, Paris, France
| | - Marine Merandet
- Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010, Paris, France
| | | | - Hongshuo Song
- Institute of Human Virology, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA
| | - David Bergerat
- Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010, Paris, France
| | - Céline Fombellida-Lopez
- Laboratory of Infectious Diseases, GIGA-I3, GIGA-Institute University of Liege, 4000, Liege, Belgium
| | - Armand Bensussan
- Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010, Paris, France
| | - Jean-David Bouaziz
- Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010, Paris, France
- Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Arsène Burny
- Laboratory of Molecular Biology, Gembloux Agrobiotech, University of Liège, Liège, Belgium
- Global Virus Network, Baltimore, MD, 21201, USA
| | - Gilles Darcis
- Laboratory of Infectious Diseases, GIGA-I3, GIGA-Institute University of Liege, 4000, Liege, Belgium
| | - Mohammad M Sajadi
- Institute of Human Virology, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA
- Global Virus Network, Baltimore, MD, 21201, USA
- University of Maryland School of Medicine, Baltimore, MD, 21201, USA
| | - Shyamasundaran Kottilil
- Institute of Human Virology, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA
- Global Virus Network, Baltimore, MD, 21201, USA
- University of Maryland School of Medicine, Baltimore, MD, 21201, USA
- Program in Oncology, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, 21201, USA
| | | | - Robert C Gallo
- Institute of Human Virology, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA.
- University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
| |
Collapse
|
5
|
Calugareanu A, Specque F, Demouche S, Grolleau C, Dobos G, Merandet M, Bergerat D, Peltier S, Jachiet M, Cassius C, Mahevas T, Saussine A, How-Kit A, Onifarasoaniaina R, Serror K, Bohec M, Baulande S, Lepelletier C, Mrad M, Charvet E, Masson AD, Boccara D, Battistella M, Buanec HL, Bouaziz JD. Transcriptomic Landscape of Prurigo Nodularis Lesional Skin CD3+ T Cells Using Single-Cell RNA Sequencing. J Invest Dermatol 2023; 143:2525-2529.e5. [PMID: 37263486 DOI: 10.1016/j.jid.2023.05.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2022] [Revised: 04/28/2023] [Accepted: 05/04/2023] [Indexed: 06/03/2023]
Affiliation(s)
- Andreea Calugareanu
- INSERM U976, Hôpital Saint-Louis, Paris, France; Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Florian Specque
- Clinical Research and Bioinformatics Unit, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Sarah Demouche
- INSERM U976, Hôpital Saint-Louis, Paris, France; Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Chloe Grolleau
- INSERM U976, Hôpital Saint-Louis, Paris, France; Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Gabor Dobos
- Skin Tumor Centre Charité (HTCC), Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | | | | | | | - Marie Jachiet
- Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Charles Cassius
- INSERM U976, Hôpital Saint-Louis, Paris, France; Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Thibault Mahevas
- Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Anne Saussine
- Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | | | | | - Kevin Serror
- INSERM U976, Hôpital Saint-Louis, Paris, France; Department of Plastic Surgery and Burn Unit, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Mylène Bohec
- Institut Curie Genomics of Excellence (ICGex) Platform, Paris, France
| | - Sylvain Baulande
- Institut Curie Genomics of Excellence (ICGex) Platform, Paris, France
| | - Clemence Lepelletier
- Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Marc Mrad
- Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Estelle Charvet
- Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Adèle de Masson
- INSERM U976, Hôpital Saint-Louis, Paris, France; Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - David Boccara
- INSERM U976, Hôpital Saint-Louis, Paris, France; Institut Cochin, INSERM U1016, CNRS UMR8104, Université de Paris, Paris, France; Université de Paris, Paris, France
| | - Maxime Battistella
- INSERM U976, Hôpital Saint-Louis, Paris, France; Université de Paris, Paris, France; Pathology department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | | | - Jean-David Bouaziz
- INSERM U976, Hôpital Saint-Louis, Paris, France; Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France.
| |
Collapse
|
6
|
Le Buanec H, Schiavon V, Merandet M, How-Kit A, Song H, Bergerat D, Fombellida-Lopez C, Bensussan A, Bouaziz JD, Burny A, Darcis G, Sajadi MM, Kottilil S, Zagury D, Gallo RC. IFNα induces CCR5 in CD4 + T-cells, causing its anti- HIV inefficiency and its subsequent pathogenic elevation, partially controlled by anti-HIV therapy. Res Sq 2023:rs.3.rs-2813616. [PMID: 37214795 PMCID: PMC10197818 DOI: 10.21203/rs.3.rs-2813616/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Like EC, we find that ART-treated patients control serum IFNα concentration and show few immune cell alterations enabling a healthy but fragile medical status. However, treatment interruption leads to elevated IFNα reflecting virus production indicating that like EC, ART does not achieve a virological cure. The immune system becomes overwhelmed by multiple immune cell abnormalities as found in untreated patients. These are chiefly mediated by elevated IFNα inducing signaling checkpoints abnormalities, including PD1, in cytotoxic immune cells. Importantly, during acute infection, elevated IFNα correlated with HIV load and we found that IFNα enhances CCR5, the HIV coreceptor in CD4+ T-cells, impairing its anti-viral response and accounting for the pathogenic vicious cycle: HIV → IFNα ↗ → infected CD4+ T-cells ↗ →HIV ↗. This study opens immunotherapeutic perspectives showing the need to control IFNα in order to convert ART patients into EC.
Collapse
Affiliation(s)
- Hélène Le Buanec
- Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France
| | - Valérie Schiavon
- Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France
| | - Marine Merandet
- Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France
| | | | - Hongshuo Song
- Institute of Human Virology, School of Medicine, University of Maryland; Baltimore MD, 21201, USA, Department of Medicine, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA
| | - David Bergerat
- Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France
| | - Céline Fombellida-Lopez
- Laboratory of Infectious Diseases, GIGA-I3, GIGA-Institute University of Liege; 4000 Liege, Belgium
| | - Armand Bensussan
- Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France
| | - Jean-David Bouaziz
- Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France
- Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Arsène Burny
- Laboratory of Molecular Biology, Gembloux Agrobiotech,University of Liège ;Belgium
- Global Virus Network, Baltimore, MD 21201, USA
| | - Gilles Darcis
- Laboratory of Infectious Diseases, GIGA-I3, GIGA-Institute University of Liege; 4000 Liege, Belgium
| | - Mohammad M. Sajadi
- Institute of Human Virology, School of Medicine, University of Maryland; Baltimore MD, 21201, USA, Department of Medicine, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA
- Global Virus Network, Baltimore, MD 21201, USA
| | - Shyamasundaran Kottilil
- Institute of Human Virology, School of Medicine, University of Maryland; Baltimore MD, 21201, USA, Department of Medicine, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA
- Global Virus Network, Baltimore, MD 21201, USA
- University of Maryland School of Medicine; Baltimore, MD 21201, USA, Program in Oncology, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD 21201, USA
| | | | - Robert C. Gallo
- Institute of Human Virology, School of Medicine, University of Maryland; Baltimore MD, 21201, USA, Department of Medicine, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA
- Global Virus Network, Baltimore, MD 21201, USA
| |
Collapse
|
7
|
Le Buanec H, Schiavon V, Merandet M, How-Kit A, Bergerat D, Fombellida-Lopez C, Bensussan A, Bouaziz JD, Burny A, Darcis G, Song H, Sajadi MM, Kottilil S, Gallo RC, Zagury D. Early Elevated IFNα Identified as the Key Mediator of HIV Pathogenesis and its low level a Hallmark of Elite Controllers. Res Sq 2023:rs.3.rs-2813601. [PMID: 37215045 PMCID: PMC10197726 DOI: 10.21203/rs.3.rs-2813601/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Advances in HIV therapy came from understanding its replication. Further progress toward "functional cure" -no therapy needed as found in Elite Controllers (EC)- may come from insights in pathogenesis and avoidance by EC. Here we show that all immune cells from HIV-infected persons are impaired in non-EC, but not in EC. Since HIV infects few cell types, these results suggest an additional mediator of pathogenesis. We identify that mediator as elevated pathogenic IFNα, controlled by EC likely by their preserved potent NK-cells and later by other killer cells. Since the earliest days of infection predict outcome genetic or chance events must be key to EC, and since we found no unique immune parameter at the onset, we suggest a chance infection with a lower HIV inoculum. These results offer an additional approach toward functional cure: a judicious targeting of IFNα for all non-EC patients.
Collapse
Affiliation(s)
- Hélène Le Buanec
- Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France
| | - Valérie Schiavon
- Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France
| | - Marine Merandet
- Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France
| | | | - David Bergerat
- Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France
| | - Céline Fombellida-Lopez
- Laboratory of Infectious Diseases, GIGA-I3, GIGA-Institute University of Liege; 4000 Liege, Belgium
| | - Armand Bensussan
- Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France
| | - Jean-David Bouaziz
- Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France
- Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Arsène Burny
- Laboratory of Molecular Biology, Gembloux Agrobiotech,University of Liège; Belgium
- Global Virus Network, Baltimore, MD 21201, USA
| | - Gilles Darcis
- Laboratory of Infectious Diseases, GIGA-I3, GIGA-Institute University of Liege; 4000 Liege, Belgium
| | - Hongshuo Song
- Institute of Human Virology, School of Medicine, University of Maryland; Baltimore MD, 21201, USA, Department of Medicine, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA
| | - Mohammad M. Sajadi
- Global Virus Network, Baltimore, MD 21201, USA
- Institute of Human Virology, School of Medicine, University of Maryland; Baltimore MD, 21201, USA, Department of Medicine, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA
| | - Shyamasundaran Kottilil
- Global Virus Network, Baltimore, MD 21201, USA
- Institute of Human Virology, School of Medicine, University of Maryland; Baltimore MD, 21201, USA, Department of Medicine, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA
- University of Maryland School of Medicine; Baltimore, MD 21201, USA, Program in Oncology, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD 21201, USA
| | - Robert C. Gallo
- Global Virus Network, Baltimore, MD 21201, USA
- Institute of Human Virology, School of Medicine, University of Maryland; Baltimore MD, 21201, USA, Department of Medicine, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA
| | | |
Collapse
|
8
|
Sonigo G, Cassius C, Battistella M, Le Buanec H, Bagot M, Saussine A, de Masson A, Lehmann-Che J, Chasset F, Jachiet M, Bouaziz JD. Acropulpitis in systemic lupus erythematosus is associated with high type 1 interferon signature. Exp Dermatol 2021; 31:819-820. [PMID: 34699626 DOI: 10.1111/exd.14485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2021] [Revised: 09/01/2021] [Accepted: 10/16/2021] [Indexed: 11/26/2022]
Affiliation(s)
- Gabrielle Sonigo
- Dermatology Department, AP-HP, Hôpital Saint-Louis, Paris, France
| | - Charles Cassius
- Dermatology Department, AP-HP, Hôpital Saint-Louis, Paris, France.,Institut de Recherche Saint-Louis, Inserm U976 - HIPI Unit, Universite ́ de Paris, Paris, France
| | - Maxime Battistella
- Institut de Recherche Saint-Louis, Inserm U976 - HIPI Unit, Universite ́ de Paris, Paris, France.,Pathology Department, AP-HP, Hôpital Saint-Louis, Paris, France
| | - Hélène Le Buanec
- Institut de Recherche Saint-Louis, Inserm U976 - HIPI Unit, Universite ́ de Paris, Paris, France
| | - Martine Bagot
- Dermatology Department, AP-HP, Hôpital Saint-Louis, Paris, France.,Institut de Recherche Saint-Louis, Inserm U976 - HIPI Unit, Universite ́ de Paris, Paris, France
| | - Anne Saussine
- Dermatology Department, AP-HP, Hôpital Saint-Louis, Paris, France
| | - Adèle de Masson
- Dermatology Department, AP-HP, Hôpital Saint-Louis, Paris, France.,Institut de Recherche Saint-Louis, Inserm U976 - HIPI Unit, Universite ́ de Paris, Paris, France
| | - Jacqueline Lehmann-Che
- Institut de Recherche Saint-Louis, Inserm U976 - HIPI Unit, Universite ́ de Paris, Paris, France.,Molecular Oncology Unit, AP-HP, Hôpital Saint-Louis, Paris, France
| | - François Chasset
- Dermatology Department, APHP, Hôpital Tenon, Sorbonne Université Faculté de médecine, Paris, France
| | - Marie Jachiet
- Dermatology Department, AP-HP, Hôpital Saint-Louis, Paris, France
| | - Jean-David Bouaziz
- Dermatology Department, AP-HP, Hôpital Saint-Louis, Paris, France.,Institut de Recherche Saint-Louis, Inserm U976 - HIPI Unit, Universite ́ de Paris, Paris, France
| |
Collapse
|
9
|
de Masson A, Darbord D, Dobos G, Boisson M, Roelens M, Ram-Wolff C, Cassius C, Le Buanec H, de la Grange P, Jouenne F, Louveau B, Sadoux A, Bouaziz JD, Marie-Cardine A, Bagot M, Moins-Teisserenc H, Mourah S, Battistella M. Macrophage-derived CXCL9 and CXCL11 recruit CD8 T cells in skin and provide long-term disease control in mogamulizumab-treated CTCL patients. Eur J Cancer 2021. [DOI: 10.1016/s0959-8049(21)00662-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
10
|
Cassius C, Branchtein M, Battistella M, Amode R, Lepelletier C, Jachiet M, de Masson A, Frumholtz L, Chasset F, Amoura Z, Mathian A, Samri A, Monfort JB, Bachmeyer C, Bengoufa D, Cordoliani F, Bagot M, Bensussan A, Bouaziz JD, Le Buanec H. Persistent deficiency of mucosal-associated invariant T cells during dermatomyositis. Rheumatology (Oxford) 2021; 59:2282-2286. [PMID: 31846040 DOI: 10.1093/rheumatology/kez564] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2019] [Revised: 10/22/2019] [Indexed: 12/31/2022] Open
Abstract
OBJECTIVES Mucosal-associated invariant T (MAIT) cells are innate-like lymphocytes that are important for antibacterial immunity and may have regulatory roles. MAIT cells are decreased during SLE. However, their frequencies and phenotype have not been investigated in DM. We studied MAIT cell frequencies and phenotype in DM patients with active and inactive disease (after treatment). METHODS Peripheral blood flow cytometry analysis of MAIT cells was compared between DM (n = 22), SLE (n = 10), psoriasis (n = 7) and atopic dermatitis (n = 5) patients, and healthy controls (n = 19). RESULTS A dramatic decrease of circulating MAIT cell frequency was observed in active DM and SLE patients compared with healthy controls and other inflammatory skin diseases [active DM: median = 0.25% (interquartile range 0.19-0.6%), P < 0.0001; active SLE: median = 0.61 (0.55-0.77), P < 0.0001 vs healthy controls: 2.32% (1.18-4.45%)]. MAIT cells from active DM patients had an abnormal phenotype including increased expression of CD25 and cytotoxic T-lymphocyte-associated protein 4 that correlated with their low frequency in the blood. CONCLUSION In DM, peripheral blood MAIT cells are dramatically reduced and have an activated/exhausted phenotype that may be linked to increased activation-induced cell death.
Collapse
Affiliation(s)
- Charles Cassius
- Université de Paris, Inserm U976 - HIPI Unit, Institut de Recherche Saint-Louis
- Dermatology Department, AP-HP, Hôpital Saint-Louis, Paris
- Université Catholique de Louvain, CHU UCL Namur, Godinne
- EMSED (etude des maladies systémiques en Dermatologie), Paris, France
| | - Mylene Branchtein
- Institut Jules Bordet, Université Libre de Belgique, Bruxelles, Belgium
| | - Maxime Battistella
- Université de Paris, Inserm U976 - HIPI Unit, Institut de Recherche Saint-Louis
- Pathology Department, AP-HP, Hôpital Saint-Louis
| | - Reyhan Amode
- Université de Paris, Inserm U976 - HIPI Unit, Institut de Recherche Saint-Louis
- Dermatology Department, AP-HP, Hôpital Saint-Louis, Paris
- EMSED (etude des maladies systémiques en Dermatologie), Paris, France
| | - Clémence Lepelletier
- Université de Paris, Inserm U976 - HIPI Unit, Institut de Recherche Saint-Louis
- Dermatology Department, AP-HP, Hôpital Saint-Louis, Paris
- EMSED (etude des maladies systémiques en Dermatologie), Paris, France
| | - Marie Jachiet
- Dermatology Department, AP-HP, Hôpital Saint-Louis, Paris
- EMSED (etude des maladies systémiques en Dermatologie), Paris, France
| | - Adèle de Masson
- Université de Paris, Inserm U976 - HIPI Unit, Institut de Recherche Saint-Louis
- Dermatology Department, AP-HP, Hôpital Saint-Louis, Paris
| | - Laure Frumholtz
- Dermatology Department, AP-HP, Hôpital Saint-Louis, Paris
- EMSED (etude des maladies systémiques en Dermatologie), Paris, France
| | - François Chasset
- EMSED (etude des maladies systémiques en Dermatologie), Paris, France
- Dermatology Department, AP-HP, Hôpital Tenon
- Sorbonne Université, Faculté de médecine sorbonne université, Paris
| | - Zahir Amoura
- Groupement Hospitalier Pitié-Salpétrère, AP-HP, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Mé decine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris)
| | - Alexis Mathian
- Groupement Hospitalier Pitié-Salpétrère, AP-HP, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Mé decine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris)
| | - Assia Samri
- Groupement Hospitalier Pitié-Salpétrère, AP-HP, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Mé decine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris)
| | | | | | | | | | - Martine Bagot
- Université de Paris, Inserm U976 - HIPI Unit, Institut de Recherche Saint-Louis
- Dermatology Department, AP-HP, Hôpital Saint-Louis, Paris
| | - Armand Bensussan
- Université de Paris, Inserm U976 - HIPI Unit, Institut de Recherche Saint-Louis
| | - Jean-David Bouaziz
- Université de Paris, Inserm U976 - HIPI Unit, Institut de Recherche Saint-Louis
- Dermatology Department, AP-HP, Hôpital Saint-Louis, Paris
- EMSED (etude des maladies systémiques en Dermatologie), Paris, France
| | - Hélène Le Buanec
- Université de Paris, Inserm U976 - HIPI Unit, Institut de Recherche Saint-Louis
| |
Collapse
|
11
|
Cassius C, Amode R, Delord M, Battistella M, Poirot J, How-Kit A, Lepelletier C, Jachiet M, de Masson A, Frumholtz L, Cordoliani F, Boccara D, Lehmann-Che J, Wong J, Dubanchet S, Alberdi AJ, Merandet M, Bagot M, Bensussan A, Bouaziz JD, Le Buanec H. MDA5 + Dermatomyositis Is Associated with Stronger Skin Type I Interferon Transcriptomic Signature with Upregulation of IFN-κ Transcript. J Invest Dermatol 2020; 140:1276-1279.e7. [PMID: 31955963 DOI: 10.1016/j.jid.2019.10.020] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2019] [Revised: 10/04/2019] [Accepted: 10/16/2019] [Indexed: 11/24/2022]
Affiliation(s)
- Charles Cassius
- Université de Paris, Inserm U976 - HIPI Unit, Institut de Recherche Saint-Louis, Paris, France; Dermatology Department, AP-HP, Hôpital Saint-Louis, Paris, France; Université Catholique de Louvain, CHU UCL Namur, Belgium; EMSED (Etude des Maladies Systémiques en Dermatologie, Société Française de Dermatologie/Study Group of Systemic Diseases in Dermatology, French Society of Dermatology), Paris, France
| | - Reyhan Amode
- Université de Paris, Inserm U976 - HIPI Unit, Institut de Recherche Saint-Louis, Paris, France; Dermatology Department, AP-HP, Hôpital Saint-Louis, Paris, France; EMSED (Etude des Maladies Systémiques en Dermatologie, Société Française de Dermatologie/Study Group of Systemic Diseases in Dermatology, French Society of Dermatology), Paris, France
| | - Marc Delord
- Direction à la recherche clinique et à l'innovation, Centre hospitalier de Versailles, Le Chesnay, France
| | - Maxime Battistella
- Université de Paris, Inserm U976 - HIPI Unit, Institut de Recherche Saint-Louis, Paris, France; Pathology Department, AP-HP, Hôpital Saint-Louis, Paris, France
| | - Justine Poirot
- Université de Paris, Inserm U976 - HIPI Unit, Institut de Recherche Saint-Louis, Paris, France
| | - Alexandre How-Kit
- Laboratory for Genomics, Foundation Jean Dausset-CEPH, Paris, France
| | - Clémence Lepelletier
- Université de Paris, Inserm U976 - HIPI Unit, Institut de Recherche Saint-Louis, Paris, France; Dermatology Department, AP-HP, Hôpital Saint-Louis, Paris, France; EMSED (Etude des Maladies Systémiques en Dermatologie, Société Française de Dermatologie/Study Group of Systemic Diseases in Dermatology, French Society of Dermatology), Paris, France
| | - Marie Jachiet
- Dermatology Department, AP-HP, Hôpital Saint-Louis, Paris, France; EMSED (Etude des Maladies Systémiques en Dermatologie, Société Française de Dermatologie/Study Group of Systemic Diseases in Dermatology, French Society of Dermatology), Paris, France
| | - Adèle de Masson
- Université de Paris, Inserm U976 - HIPI Unit, Institut de Recherche Saint-Louis, Paris, France; Dermatology Department, AP-HP, Hôpital Saint-Louis, Paris, France
| | - Laure Frumholtz
- Dermatology Department, AP-HP, Hôpital Saint-Louis, Paris, France; EMSED (Etude des Maladies Systémiques en Dermatologie, Société Française de Dermatologie/Study Group of Systemic Diseases in Dermatology, French Society of Dermatology), Paris, France
| | | | - David Boccara
- Université de Paris, Inserm U976 - HIPI Unit, Institut de Recherche Saint-Louis, Paris, France; Plastic, Reconstructive, and Cosmetic and Burn Surgery Unit, AP-HP, Hôpital Saint-Louis, Paris, France
| | - Jacqueline Lehmann-Che
- Université de Paris, Inserm U976 - HIPI Unit, Institut de Recherche Saint-Louis, Paris, France; Molecular Oncology Unit, AP-HP, Hôpital Saint-Louis, Paris, France
| | - Jennifer Wong
- Molecular Oncology Unit, AP-HP, Hôpital Saint-Louis, Paris, France
| | - Sylvie Dubanchet
- Université de Paris, Inserm U976 - HIPI Unit, Institut de Recherche Saint-Louis, Paris, France
| | - Antonio José Alberdi
- Université de Paris, Technological Core Facility, Institut de Recherche Saint-Louis, Hôpital Saint-Louis, Paris, France
| | - Marine Merandet
- Université de Paris, Inserm U976 - HIPI Unit, Institut de Recherche Saint-Louis, Paris, France
| | - Martine Bagot
- Université de Paris, Inserm U976 - HIPI Unit, Institut de Recherche Saint-Louis, Paris, France; Dermatology Department, AP-HP, Hôpital Saint-Louis, Paris, France
| | - Armand Bensussan
- Université de Paris, Inserm U976 - HIPI Unit, Institut de Recherche Saint-Louis, Paris, France
| | - Jean-David Bouaziz
- Université de Paris, Inserm U976 - HIPI Unit, Institut de Recherche Saint-Louis, Paris, France; Dermatology Department, AP-HP, Hôpital Saint-Louis, Paris, France; EMSED (Etude des Maladies Systémiques en Dermatologie, Société Française de Dermatologie/Study Group of Systemic Diseases in Dermatology, French Society of Dermatology), Paris, France.
| | - Hélène Le Buanec
- Université de Paris, Inserm U976 - HIPI Unit, Institut de Recherche Saint-Louis, Paris, France
| |
Collapse
|
12
|
Joffre J, Hau E, Zeboudj L, Laurans L, Battistella M, Boufenzer A, Masson A, Le Buanec H, Cochaud S, Bagot M, Bensussan A, Gibot S, Bouaziz JD, Ait-Oufella H. Trem-1 is not crucial in psoriasiform imiquimod-induced skin inflammation in mice. Exp Dermatol 2018; 25:400-2. [PMID: 26782119 DOI: 10.1111/exd.12944] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/08/2016] [Indexed: 01/09/2023]
Affiliation(s)
- Jérémie Joffre
- Paris Cardiovascular Research Center, INSERM U970 and Université Paris-Descartes, Paris, France.,Medical Intensive Care Unit, CHU Saint-Antoine and Université Pierre-et-Marie Curie, Paris, France
| | - Estelle Hau
- INSERM and UMRS 976, Laboratory of Oncodermatology, Immunology and Cutaneous Stem cells, Paris, France.,University Paris Diderot, Sorbonne Paris Cité, Paris, France.,Dermatology Department, Saint-Louis Hospital, Paris, France
| | - Lynda Zeboudj
- Paris Cardiovascular Research Center, INSERM U970 and Université Paris-Descartes, Paris, France
| | - Ludivine Laurans
- Paris Cardiovascular Research Center, INSERM U970 and Université Paris-Descartes, Paris, France
| | - Maxime Battistella
- Pathology Department Saint-Louis Hospital and INSERM UMRS 1165, Paris, France
| | | | - Adèlede Masson
- INSERM and UMRS 976, Laboratory of Oncodermatology, Immunology and Cutaneous Stem cells, Paris, France.,University Paris Diderot, Sorbonne Paris Cité, Paris, France.,Dermatology Department, Saint-Louis Hospital, Paris, France
| | - Hélène Le Buanec
- INSERM and UMRS 976, Laboratory of Oncodermatology, Immunology and Cutaneous Stem cells, Paris, France.,University Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Stéphanie Cochaud
- INSERM and UMRS 976, Laboratory of Oncodermatology, Immunology and Cutaneous Stem cells, Paris, France.,University Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Martine Bagot
- INSERM and UMRS 976, Laboratory of Oncodermatology, Immunology and Cutaneous Stem cells, Paris, France.,University Paris Diderot, Sorbonne Paris Cité, Paris, France.,Dermatology Department, Saint-Louis Hospital, Paris, France
| | - Armand Bensussan
- INSERM and UMRS 976, Laboratory of Oncodermatology, Immunology and Cutaneous Stem cells, Paris, France.,University Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Sébastien Gibot
- Inserm UMR_S1116, Faculté de Médecine de Nancy, University of Lorraine, Nancy, France.,Medical Intensive Care Unit, Hôpital Central, CHU Nancy, Nancy, France
| | - Jean-David Bouaziz
- INSERM and UMRS 976, Laboratory of Oncodermatology, Immunology and Cutaneous Stem cells, Paris, France.,University Paris Diderot, Sorbonne Paris Cité, Paris, France.,Dermatology Department, Saint-Louis Hospital, Paris, France
| | - Hafid Ait-Oufella
- Paris Cardiovascular Research Center, INSERM U970 and Université Paris-Descartes, Paris, France.,Medical Intensive Care Unit, CHU Saint-Antoine and Université Pierre-et-Marie Curie, Paris, France
| |
Collapse
|
13
|
Cassius C, Jachiet M, Branchtein M, Dubanchet S, Bagot M, Baroudjian B, Salle de Chou C, Gottlieb J, Battistella M, Bensussan A, Bouaziz JD, Le Buanec H. Modifications lymphocytaires T dans la dermatomyosite amyopathique. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
14
|
Chasset F, de Masson A, Le Buanec H, Xhaard A, de Fontbrune FS, Robin M, Rybojad M, Parquet N, Brignier AC, Coman T, Bengoufa D, Bergeron A, Peffault de Latour R, Bagot M, Bensussan A, Socié G, Bouaziz JD. APRIL levels are associated with disease activity in human chronic graft-versus-host disease. Haematologica 2016; 101:e312-5. [PMID: 26992945 DOI: 10.3324/haematol.2016.145409] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- François Chasset
- INSERM and UMRS 976, Laboratory of Onco dermatology, Immunology, and Cutaneous Stem cells, F-75739 Paris University Paris Diderot, Sorbonne Paris Cité Dermatology Department, Saint-Louis Hospital, Paris
| | - Adèle de Masson
- INSERM and UMRS 976, Laboratory of Onco dermatology, Immunology, and Cutaneous Stem cells, F-75739 Paris University Paris Diderot, Sorbonne Paris Cité Dermatology Department, Saint-Louis Hospital, Paris
| | - Hélène Le Buanec
- INSERM and UMRS 976, Laboratory of Onco dermatology, Immunology, and Cutaneous Stem cells, F-75739 Paris University Paris Diderot, Sorbonne Paris Cité
| | - Aliénor Xhaard
- University Paris Diderot, Sorbonne Paris Cité Hematology and Transplantation, Saint-Louis Hospital, Paris
| | - Flore Sicre de Fontbrune
- University Paris Diderot, Sorbonne Paris Cité Hematology and Transplantation, Saint-Louis Hospital, Paris
| | - Marie Robin
- University Paris Diderot, Sorbonne Paris Cité Hematology and Transplantation, Saint-Louis Hospital, Paris
| | - Michel Rybojad
- University Paris Diderot, Sorbonne Paris Cité Dermatology Department, Saint-Louis Hospital, Paris
| | - Nathalie Parquet
- University Paris Diderot, Sorbonne Paris Cité Hematology and Transplantation, Saint-Louis Hospital, Paris Therapeutic Apheresis Unit, Saint-Louis Hospital, Paris
| | - Anne C Brignier
- University Paris Diderot, Sorbonne Paris Cité Hematology and Transplantation, Saint-Louis Hospital, Paris Therapeutic Apheresis Unit, Saint-Louis Hospital, Paris
| | - Tereza Coman
- University Paris Diderot, Sorbonne Paris Cité Hematology and Transplantation, Saint-Louis Hospital, Paris
| | - Djaouida Bengoufa
- University Paris Diderot, Sorbonne Paris Cité Immunobiology Department, Saint-Louis Hospital, Paris
| | - Anne Bergeron
- University Paris Diderot, Sorbonne Paris Cité Pneumology Department, Saint-Louis Hospital, Paris
| | - Régis Peffault de Latour
- University Paris Diderot, Sorbonne Paris Cité Hematology and Transplantation, Saint-Louis Hospital, Paris
| | - Martine Bagot
- INSERM and UMRS 976, Laboratory of Onco dermatology, Immunology, and Cutaneous Stem cells, F-75739 Paris University Paris Diderot, Sorbonne Paris Cité Dermatology Department, Saint-Louis Hospital, Paris
| | - Armand Bensussan
- INSERM and UMRS 976, Laboratory of Onco dermatology, Immunology, and Cutaneous Stem cells, F-75739 Paris University Paris Diderot, Sorbonne Paris Cité
| | - Gérard Socié
- University Paris Diderot, Sorbonne Paris Cité Hematology and Transplantation, Saint-Louis Hospital, Paris INSERM and UMRS1160, France
| | - Jean-David Bouaziz
- INSERM and UMRS 976, Laboratory of Onco dermatology, Immunology, and Cutaneous Stem cells, F-75739 Paris University Paris Diderot, Sorbonne Paris Cité Dermatology Department, Saint-Louis Hospital, Paris
| |
Collapse
|
15
|
Chasset F, Le Buanec H, Sicre de Fontbrune F, de Masson A, Rivet J, Bergeron A, Bagot M, Socié G, Bensussan A, Bouaziz JD. Evidence of Th1, Th17 and Tc17 cells in psoriasiform chronic graft-versus-host disease. Exp Dermatol 2015; 25:64-5. [PMID: 26343416 DOI: 10.1111/exd.12857] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/02/2015] [Indexed: 11/29/2022]
Affiliation(s)
- François Chasset
- INSERM and UMRS 976, Laboratory of Oncodermatology, Immunology, and Cutaneous Stem Cells, Paris, France.,University Paris Diderot, Sorbonne Paris Cité, Paris, France.,Dermatology Department, Saint-Louis Hospital, Paris, France
| | - Hélène Le Buanec
- INSERM and UMRS 976, Laboratory of Oncodermatology, Immunology, and Cutaneous Stem Cells, Paris, France.,University Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Flore Sicre de Fontbrune
- University Paris Diderot, Sorbonne Paris Cité, Paris, France.,Hematology and Transplantation, Saint-Louis Hospital, Paris, France
| | - Adèle de Masson
- INSERM and UMRS 976, Laboratory of Oncodermatology, Immunology, and Cutaneous Stem Cells, Paris, France.,University Paris Diderot, Sorbonne Paris Cité, Paris, France.,Dermatology Department, Saint-Louis Hospital, Paris, France
| | - Jacqueline Rivet
- University Paris Diderot, Sorbonne Paris Cité, Paris, France.,Pathology Department, Saint Louis Hospital, Paris, France
| | - Anne Bergeron
- University Paris Diderot, Sorbonne Paris Cité, Paris, France.,Pneumology Department, Saint-Louis Hospital, Paris, France
| | - Martine Bagot
- INSERM and UMRS 976, Laboratory of Oncodermatology, Immunology, and Cutaneous Stem Cells, Paris, France.,University Paris Diderot, Sorbonne Paris Cité, Paris, France.,Dermatology Department, Saint-Louis Hospital, Paris, France
| | - Gérard Socié
- University Paris Diderot, Sorbonne Paris Cité, Paris, France.,Hematology and Transplantation, Saint-Louis Hospital, Paris, France
| | - Armand Bensussan
- INSERM and UMRS 976, Laboratory of Oncodermatology, Immunology, and Cutaneous Stem Cells, Paris, France.,University Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Jean-David Bouaziz
- INSERM and UMRS 976, Laboratory of Oncodermatology, Immunology, and Cutaneous Stem Cells, Paris, France.,University Paris Diderot, Sorbonne Paris Cité, Paris, France.,Dermatology Department, Saint-Louis Hospital, Paris, France
| |
Collapse
|
16
|
|
17
|
Abstract
The analysis of human B cell populations of the blood relies on the expression of surface markers, mainly CD19, CD24, CD38, and CD27. According to these surface markers, three main B cell subsets can be identified in the blood: immature transitional B cells (CD19(+)CD24(high)CD38(high)), naïve B cells (CD19(+)CD24(int)CD38(int)) that have not encountered an antigen, and memory B cells (CD19(+)CD27(+)). To date, human B cells with regulatory functions have been essentially described within the CD24(high)CD38(high) transitional B cell subset. CD24(high)CD38(high) transitional B cells are able to produce interleukin 10 (IL-10) and to regulate in vitro Th1 and Th17 CD4(+) T cell activation. Here, we provide the methods to analyze and purify the CD24(high)CD38(high) transitional B cell subset for further in vitro experiments. We also provide a reliable method to detect B cell IL-10 production using intracellular cytokine staining.
Collapse
|
18
|
Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, Veys I, Haibe-Kains B, Singhal SK, Michiels S, Rothé F, Salgado R, Duvillier H, Ignatiadis M, Desmedt C, Bron D, Larsimont D, Piccart M, Sotiriou C, Willard-Gallo K. CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 2013; 123:2873-92. [PMID: 23778140 DOI: 10.1172/jci67428] [Citation(s) in RCA: 688] [Impact Index Per Article: 62.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2012] [Accepted: 04/25/2013] [Indexed: 12/13/2022] Open
Abstract
CD4⁺ T cells are critical regulators of immune responses, but their functional role in human breast cancer is relatively unknown. The goal of this study was to produce an image of CD4⁺ T cells infiltrating breast tumors using limited ex vivo manipulation to better understand the in vivo differences associated with patient prognosis. We performed comprehensive molecular profiling of infiltrating CD4⁺ T cells isolated from untreated invasive primary tumors and found that the infiltrating T cell subpopulations included follicular helper T (Tfh) cells, which have not previously been found in solid tumors, as well as Th1, Th2, and Th17 effector memory cells and Tregs. T cell signaling pathway alterations included a mixture of activation and suppression characterized by restricted cytokine/chemokine production, which inversely paralleled lymphoid infiltration levels and could be reproduced in activated donor CD4⁺ T cells treated with primary tumor supernatant. A comparison of extensively versus minimally infiltrated tumors showed that CXCL13-producing CD4⁺ Tfh cells distinguish extensive immune infiltrates, principally located in tertiary lymphoid structure germinal centers. An 8-gene Tfh signature, signifying organized antitumor immunity, robustly predicted survival or preoperative response to chemotherapy. Our identification of CD4⁺ Tfh cells in breast cancer suggests that they are an important immune element whose presence in the tumor is a prognostic factor.
Collapse
Affiliation(s)
- Chunyan Gu-Trantien
- Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Bouaziz JD, Buanec HL, Zagury D, Bagot M, Bensussan A. Actualités sur l’immunothérapie anti-cytokine par les vaccins kinoïdes dans le traitement des maladies inflammatoires. Med Sci (Paris) 2013; 29:669-70. [DOI: 10.1051/medsci/2013296023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Le Buanec H, Sené T, Bensussan A, Gallo R, Zagury D. The dual (activating/suppressive) effect of extracellular TatHIV-1 is driven by the infalmmatory microenvironment of infected lymphoid foci. Retrovirology 2012. [PMCID: PMC3360303 DOI: 10.1186/1742-4690-9-s1-p35] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
21
|
Abstract
Anticytokine (AC) immune therapies derived from vaccine procedures aim at enhancing natural immune defense mechanisms ineffective to contain abnormally produced cytokines and counteract their pathogenic effects. Given their short half-life, cytokines, the production of which by effector immune cells (T and B lymphocytes, antigen-presenting cells (APCs), natural killer (NK) and endothelial cells) is inducible and controlled by negative feedback regulation, (1) exert locally their signaling to paracrine/autocrine target responder cells carrying high-affinity membrane receptors and (2) are commonly present at minimal concentration in the body fluid (lymph, serum). Aberrant signaling triggered by cytokines, uncontrolly released by effector immune cells or produced by cancer and other pathologic cells, contribute to the pathogenesis of chronic diseases including cancer, viral infections, allergy, and autoimmunity. To block these ectopic cytokine signaling and prevent their pathogenic effects, AC Abs supplied either by injections (passive AC immune therapy) or elicited by immunization with cytokine-derived immunogenes called Kinoids (active AC immune therapy) proved to be experimentally effective and safe. In this review, we detailed the rationale and the requirements for the use of AC immunotherapies in humans, the proof of efficacy of these medications in animal disease models, and their current clinical development and outcome, including adverse side effects they may generate. We particularly show that, to date, the benefit:risk ratio of AC immune therapies is highly positive.
Collapse
|
22
|
Le Buanec H, Paturance S, Couillin I, Schnyder-Candrian S, Larcier P, Ryffel B, Bizzini B, Bensussan A, Burny A, Gallo R, Zagury D, Peltre G. Control of allergic reactions in mice by an active anti-murine IL-4 immunization. Vaccine 2007; 25:7206-16. [PMID: 17719148 DOI: 10.1016/j.vaccine.2007.07.029] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2007] [Revised: 07/06/2007] [Accepted: 07/15/2007] [Indexed: 11/18/2022]
Abstract
Pathogenesis of allergic inflammatory disorders is characterized by allergen-induced IgE stimulated by Th2 cytokines including mainly IL-4 overproduction. To counteract IL-4 effects in sensitized-BALB/c mice, we prepared an IL-4 derivative immunogen, made of KLH and murine IL-4 heterocomplex, termed mIL-4 kinoid. Murine IL-4 kinoid immunized mice produced high titer of anti-IL-4 neutralizing Abs. In contrast to KLH control immunization kinoid immunization reversed the allergic IgE:IgG ratio hallmark in rBet v 1a sensitized mice and reduced pulmonary eosinophil recruitment and bronchial hyperreactivity in Ova-sensitized mice. These data pave the way to alternative therapies to combat allergic conditions.
Collapse
|
23
|
Rad FH, Le Buanec H, Paturance S, Larcier P, Genne P, Ryffel B, Bensussan A, Bizzini B, Gallo RC, Zagury D, Uzan G. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci U S A 2007; 104:2837-42. [PMID: 17301234 PMCID: PMC1797624 DOI: 10.1073/pnas.0611022104] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Tumor growth depends on blood supply, requiring the development of new vessels, and vascular endothelial growth factor (VEGF) plays a central role in neoangiogenic processes. For this reason, VEGF represents a target for the development of new therapeutic antiangiogenic molecules. Clinical trials using anti-VEGF mAbs such as bevacizumab have validated the efficacy of this therapeutic approach but have also revealed adverse effects. Here we report that a VEGF-derived immunogen, consisting of a heterocomplex of a murine (m)VEGF and keyhole limpet hemocyanin, called "mVEGF kinoid," triggered a strong Ab immune response in mice. The anti-VEGF Abs inhibited both the proliferation of human umbilical vein endothelial cells cultured in the presence of mVEGF and the binding of mVEGF to its receptor-2 Flk-1. In mVEGF kinoid-immunized BALB/c mice challenged with syngeneic CT26 colorectal tumor cells, the number and size of lung metastases were significantly decreased. In human (h)VEGF kinoid-immunized BALB/c mice, high levels of serum Abs to hVEGF were present, and purified IgG from these mice decreased by > or =50% the tumor growth of human A673 rhabdomyosarcoma cells and HT29 colon carcinoma xenografted in Swiss nude and NOD/SCID mice, respectively. Tumor cell growth inhibition was similar to that observed in mice receiving therapeutic doses of bevacizumab. These experiments suggest that a therapeutic vaccine containing VEGF kinoid may represent a strategy for safely combating VEGF-dependent neovascularization and metastases occurring in malignant tumors.
Collapse
Affiliation(s)
- Farhad Haghighi Rad
- Institut National de la Santé et de la Recherche Médicale (INSERM) U602 Microenvironnement et Physiopathologie de la Différenciation, Hôpital Paul Brousse, 12, Avenue Paul Vaillant Couturier, F-94807 Villejuif, France
| | | | | | | | - Philippe Genne
- Oncodesign, Inc., 20, Rue Jean Mazen BP 27627, F-21076 Dijon Cedex, France
| | - Bernhard Ryffel
- Centre National de la Recherche Scientifique Institut Transgenose, IEM 2815, 3B, Rue de la Ferollerie, 45071 Orleans, France
| | - Armand Bensussan
- INSERM U659, F-94010 Créteil, France
- Institut Mondor de Médecine Moléculaire, Hôpital Henri Mondor, 51, Avenue du Mal de Lattre de Tassigny, F-94010 Créteil, France; and
| | | | - Robert C. Gallo
- Institute of Human Virology, University of Maryland, 725 West Lombard Street, Suite S307, Baltimore, MD 21201
- To whom correspondence may be addressed. E-mail: or
| | - Daniel Zagury
- Neovacs S.A., 3–5, Impasse Reille, 75014 Paris, France
- To whom correspondence may be addressed. E-mail: or
| | - Georges Uzan
- Institut National de la Santé et de la Recherche Médicale (INSERM) U602 Microenvironnement et Physiopathologie de la Différenciation, Hôpital Paul Brousse, 12, Avenue Paul Vaillant Couturier, F-94807 Villejuif, France
| |
Collapse
|
24
|
Le Buanec H, Delavallée L, Bessis N, Paturance S, Bizzini B, Gallo R, Zagury D, Boissier MC. TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc Natl Acad Sci U S A 2006; 103:19442-7. [PMID: 17158801 PMCID: PMC1748245 DOI: 10.1073/pnas.0604827103] [Citation(s) in RCA: 69] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
The proinflammatory cytokine TNFalpha is a potent mediator of septic shock and a therapeutic target for chronic inflammatory pathologies including rheumatoid arthritis and Crohn's disease. As an alternative to anti-human TNFalpha (hTNFalpha) mAbs and other hTNFalpha blocker approved drugs, we developed an active anti-hTNFalpha immunotherapy, based on a vaccine comprised of a keyhole limpet hemocyanin-hTNFalpha heterocomplex immunogen (hTNFalpha kinoid) adjuvanted in incomplete Freund's adjuvant. In mice transgenic for hTNFalpha (TTg mice), hTNFalpha kinoid vaccination elicited high titers of Abs that neutralized hTNFalpha bioactivities but did not result in a cellular response to hTNFalpha. The vaccine was safe and effective in two experimental models. Kinoid-immunized but not control TTg mice resisted hTNFalpha-driven shock in one model and were prevented from spontaneous arthritis, inflammatory synovitis, and articular destruction in a second model. These data demonstrate an anti-cytokine induction of autoimmune protection against both acute and chronic hTNFalpha exposure. They show that active vaccination against a human cytokine can be achieved, and that the immune response can be effective and safe.
Collapse
Affiliation(s)
- Hélène Le Buanec
- *Neovacs, Incorporated, Université Pierre et Marie Curie, 96 Boulevard Raspail, 75006 Paris, France
| | - Laure Delavallée
- Institut National de la Santé et de la Recherche Médicale (INSERM) ERI18, 74 Rue Marcel Cachin, 93017 Bobigny, France
- Université de Paris 13, 93017 Bobigny, France
| | - Natacha Bessis
- Institut National de la Santé et de la Recherche Médicale (INSERM) ERI18, 74 Rue Marcel Cachin, 93017 Bobigny, France
- Université de Paris 13, 93017 Bobigny, France
| | - Sébastien Paturance
- *Neovacs, Incorporated, Université Pierre et Marie Curie, 96 Boulevard Raspail, 75006 Paris, France
| | - Bernard Bizzini
- *Neovacs, Incorporated, Université Pierre et Marie Curie, 96 Boulevard Raspail, 75006 Paris, France
| | - Robert Gallo
- Institute of Human Virology, University of Maryland, 725 West Lombard Street, Suite S307, Baltimore, MD 21201
| | - Daniel Zagury
- *Neovacs, Incorporated, Université Pierre et Marie Curie, 96 Boulevard Raspail, 75006 Paris, France
- To whom correspondence should be addressed. E-mail:
| | - Marie-Christophe Boissier
- Institut National de la Santé et de la Recherche Médicale (INSERM) ERI18, 74 Rue Marcel Cachin, 93017 Bobigny, France
- Assistance Publique–Hôpitaux de Paris (AP-HP), Department of Rheumatology, Avicenne Hospital, 93009 Bobigny, France; and
| |
Collapse
|
25
|
Clumeck N, Hermans P, Zagury D, Buanec HL, Burny A, Bizzini B, Gilliam B, Redfield R, Gallo R. Neutralizing anti-Tat antibodies prolonged HAART interruption in vaccines in a prospective structured interruption study. Retrovirology 2006. [PMCID: PMC1716922 DOI: 10.1186/1742-4690-3-s1-s15] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
26
|
Zagury D, Buanec HL, Burny A, Gallo RC. Follow-up of HIV Infected Patients Who Received a Therapeutic Anti-Tat Vaccination. Retrovirology 2005. [DOI: 10.1186/1742-4690-2-s1-s115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
27
|
Noonan DM, Gringeri A, Meazza R, Rosso O, Mazza S, Muça-Perja M, Le Buanec H, Accolla RS, Albini A, Ferrini S. Identification of immunodominant epitopes in inactivated Tat-vaccinated healthy and HIV-1-infected volunteers. J Acquir Immune Defic Syndr 2003; 33:47-55. [PMID: 12792355 DOI: 10.1097/00126334-200305010-00008] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
We analyzed the epitopes and the molecular forms of Tat recognized by the antibodies raised by Tat-toxoid vaccination in both healthy and HIV-infected volunteers. Tat-toxoid-vaccinated healthy volunteer sera reacted predominantly with peptides covering amino acids 1 through 24 and 46 through 60, corresponding to the N-terminus and basic domains of Tat. In contrast, whereas all sera from vaccinated HIV-1-positive patients reacted with the N-terminus and (with a single exception) with the basic domain, most of these sera also recognized peptides encompassing distinct domains of Tat, particularly the C-terminus (79-86). The sera of vaccinated individuals recognized both monomeric and oligomeric forms of Tat 1 through 86 or of Tat 1 through 101 and also blocked the ability of cell-released extracellular Tat to transactivate the HIV-1 LTR promoter. Synthetic Tat preincubated with sera from vaccinated individuals lost its functional activity as well. This is probably because of its inability to enter the cells as a result of immune complex formation with anti-Tat IgG. These data demonstrate that Tat-toxoid vaccination induces an efficient antibody response blocking the functional activity of Tat.
Collapse
Affiliation(s)
- Douglas M Noonan
- Tumor Progression Section, double dagger Immuno-Pharmacology Section, and #Molecular Biology Laboratory, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|